JPMorgan reduces its holdings in GENSCRIPT BIO (01548) by approximately 33.751 million shares at approximately HK$32.74 per share.
On September 15, JPMorgan reduced its holdings in GenScript Biotech (01548) by 33.751017 million shares at HK$32.7394 per share, for a total amount of approximately HK$1.105 billion.
The latest information from the Hong Kong Stock Exchange shows that on September 15, JPMorgan reduced its holdings in GENSCRIPT BIO (01548) by 33.751017 million shares at HK$32.7394 per share, for a total amount of approximately HK$1.105 billion. After the reduction, its latest shareholding is approximately 129 million shares, with its latest shareholding ratio at 5.64%.
Related Articles
Primarius Technologies (688206.SH) shareholders plan to reduce their holdings by no more than 2% in total.
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
Primarius Technologies (688206.SH) shareholders plan to reduce their holdings by no more than 2% in total.
General Manager Cheng Zhenghui of APT Medical Inc. (688617.SH) plans to reduce his shareholding by no more than 1.5%.
EFORT Intelligent Equipment (688165.SH) shareholder Xinwei Jishi and its concerted parties plan to reduce their shareholding by no more than 3%.
RECOMMEND
